LAVIV® (azficel-T), dermal fibroblasts for severe nasolabial fold wrinkles
LAVIV® is an autologous cellular product, composed of fibroblasts, indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. Dermal fibroblasts from post-auricular skin biopsy tissue are aseptically expanded using standard tissue culture procedures.
LAVIV® effectively improves the appearance of smile line wrinkles and proved to be safe and well-tolerated.
Read More
Contraindications: Allogeneic use of LAVIV; allergy to gentamicin, amphotericin, dimethyl sulfoxide (DMSO), or material of bovine origin; active infection in the facial area.
Former provider name: Isolagen Technologies Inc.
The product was commercially available in the United States and elsewhere without regulatory oversight and only in 2011 received FDA approval.
Read More
Product Information for
LAVIV® (azficel-T), dermal fibroblasts for severe nasolabial fold wrinkles
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access